United Lab Shares Surge Over 7% Intraday as UBS Sees Market Undervaluing UBT251 Sales Potential

Deep News

Feb 06

UNITED LAB (03933) saw its shares rise more than 7% during the trading session. At the time of writing, the stock was up 5.62%, trading at HK$13.34, with a turnover of HK$165 million.

Recently, UNITED LAB announced that its wholly-owned subsidiary, Federal Biotech (Zhuhai Hengqin) Co., Ltd., has obtained implied clinical trial approval from China's National Medical Products Administration for its self-developed Class 1 innovative drug UBT251 injection. The approval is for the treatment of moderate to severe obstructive sleep apnea (OSA) comorbid with obesity. As China's first chemically synthesized GLP-1/GIP/GCG triple-target receptor agonist new drug, UBT251 positions the company significantly within the research field of such drugs.

UBS released a research report stating that UNITED LAB is a leading pharmaceutical manufacturer in China with integrated business lines covering intermediate products, active pharmaceutical ingredients, and formulated products. Leveraging decades of research and development expertise in metabolic diseases and strong early-stage clinical results, the company licensed the ex-China rights for UBT251 to Novo Nordisk (NVO.US) in March last year. The agreement includes an upfront payment of $200 million, potential milestone payments of up to $1.8 billion, and tiered sales royalties. The report suggests that the market is underestimating the sales potential of UBT251, as well as the company's broader innovative R&D pipeline.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1175334452"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1175334452\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1175334452?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-06 10:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1175334452","market":"sg","top_or_hot":-1,"title":"United Lab Shares Surge Over 7% Intraday as UBS Sees Market Undervaluing UBT251 Sales Potential","media":"Deep News","content":"<p>UNITED LAB (03933) saw its shares rise more than 7% during the trading session. At the time of writing, the stock was up 5.62%, trading at HK$13.34, with a turnover of HK$165 million.</p>\n<p>Recently, UNITED LAB announced that its wholly-owned subsidiary, Federal Biotech (Zhuhai Hengqin) Co., Ltd., has obtained implied clinical trial approval from China's National Medical Products Administration for its self-developed Class 1 innovative drug UBT251 injection. The approval is for the treatment of moderate to severe obstructive sleep apnea (OSA) comorbid with obesity. As China's first chemically synthesized GLP-1/GIP/GCG triple-target receptor agonist new drug, UBT251 positions the company significantly within the research field of such drugs.</p>\n<p>UBS released a research report stating that UNITED LAB is a leading pharmaceutical manufacturer in China with integrated business lines covering intermediate products, active pharmaceutical ingredients, and formulated products. Leveraging decades of research and development expertise in metabolic diseases and strong early-stage clinical results, the company licensed the ex-China rights for UBT251 to Novo Nordisk (NVO.US) in March last year. The agreement includes an upfront payment of $200 million, potential milestone payments of up to $1.8 billion, and tiered sales royalties. The report suggests that the market is underestimating the sales potential of UBT251, as well as the company's broader innovative R&D pipeline.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>United Lab Shares Surge Over 7% Intraday as UBS Sees Market Undervaluing UBT251 Sales Potential</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUnited Lab Shares Surge Over 7% Intraday as UBS Sees Market Undervaluing UBT251 Sales Potential\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2026-02-06 10:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>UNITED LAB (03933) saw its shares rise more than 7% during the trading session. At the time of writing, the stock was up 5.62%, trading at HK$13.34, with a turnover of HK$165 million.</p>\n<p>Recently, UNITED LAB announced that its wholly-owned subsidiary, Federal Biotech (Zhuhai Hengqin) Co., Ltd., has obtained implied clinical trial approval from China's National Medical Products Administration for its self-developed Class 1 innovative drug UBT251 injection. The approval is for the treatment of moderate to severe obstructive sleep apnea (OSA) comorbid with obesity. As China's first chemically synthesized GLP-1/GIP/GCG triple-target receptor agonist new drug, UBT251 positions the company significantly within the research field of such drugs.</p>\n<p>UBS released a research report stating that UNITED LAB is a leading pharmaceutical manufacturer in China with integrated business lines covering intermediate products, active pharmaceutical ingredients, and formulated products. Leveraging decades of research and development expertise in metabolic diseases and strong early-stage clinical results, the company licensed the ex-China rights for UBT251 to Novo Nordisk (NVO.US) in March last year. The agreement includes an upfront payment of $200 million, potential milestone payments of up to $1.8 billion, and tiered sales royalties. The report suggests that the market is underestimating the sales potential of UBT251, as well as the company's broader innovative R&D pipeline.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03933","symbol_name":"联邦制药","start_time":0,"source_url":"","article_id":"1175334452","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1175334452","pubTimestamp":1770343950,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"UNITED LAB (03933) saw its shares rise more than 7% during the trading session. At the time of writing, the stock was up 5.62%, trading at HK$13.34, with a turnover of HK$165 million. Recently,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03933":"联邦制药","BK1191":"制药"},"translate_title":"瑞银认为市场低估了UBT251的销售潜力，联邦制药股价盘中飙升逾7%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03933":1},"content_text":"UNITED LAB (03933) saw its shares rise more than 7% during the trading session. At the time of writing, the stock was up 5.62%, trading at HK$13.34, with a turnover of HK$165 million.\nRecently, UNITED LAB announced that its wholly-owned subsidiary, Federal Biotech (Zhuhai Hengqin) Co., Ltd., has obtained implied clinical trial approval from China's National Medical Products Administration for its self-developed Class 1 innovative drug UBT251 injection. The approval is for the treatment of moderate to severe obstructive sleep apnea (OSA) comorbid with obesity. As China's first chemically synthesized GLP-1/GIP/GCG triple-target receptor agonist new drug, UBT251 positions the company significantly within the research field of such drugs.\nUBS released a research report stating that UNITED LAB is a leading pharmaceutical manufacturer in China with integrated business lines covering intermediate products, active pharmaceutical ingredients, and formulated products. Leveraging decades of research and development expertise in metabolic diseases and strong early-stage clinical results, the company licensed the ex-China rights for UBT251 to Novo Nordisk (NVO.US) in March last year. The agreement includes an upfront payment of $200 million, potential milestone payments of up to $1.8 billion, and tiered sales royalties. The report suggests that the market is underestimating the sales potential of UBT251, as well as the company's broader innovative R&D pipeline.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}